|TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies.|
Recombinant CHO-K1 cells constitutively expressing human CD155 (Poliovirus receptor, Nectin-like protein 5, GenBank accession # NM_006505).
|Stability:||32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Synonym(s):||Poliovirus receptor, Nectin-like protein 5, CD155-His|
|Freeze Medium:||90% FBS+10% DMSO|
|Culture Medium:||F12k+10%FBS+500ug/ml Hygromycin|
|Application(s):||Screen for activators or inhibitors of TIGIT signaling in a cellular context, screen CD155 antibodies for binding affinity, and characterize the biological activity of TIGIT interactions with CD155.|
|IV. Description of Host Cell Line|
|Organism:||Cricetulus griseus, hamster, Chinese|
|Disease:||Hamster Chinese ovary|
|Ⅴ. Representative Data|
Figure 1.Recombinant CHO-cells constitutively expressing CD155.